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I vividly remember an experience in the surgeons’
lounge a few years ago where a junior colleague had just
completed a difficult pancreaticoduodenectomy (PD) in a
72-year-old man with pancreatic cancer. A senior, some-
what crusty surgeon who was following his junior
colleague in the operating room and was now 2 hours late,
remarked loudly: ‘‘The only positive consequence of that
operation is that I will likely miss dinner with my daugh-
ter’s in-laws.’’
Long-term survival in pancreatic cancer remains an
uncommon occurrence; this is attributable to the advanced
stage at presentation, accelerated natural history, and the at
best modest success of systemic therapy. Despite this,
survival is the primary (if not singular) goal after PD for
resectable pancreatic cancer. On the other hand, survivor-
ship, defined as ‘‘the physical, psychosocial, and economic
issues of cancer, from diagnosis until the end of life’’ by
the National Cancer Institute, has been recognized as an
increasingly important aspect of clinical cancer research.1
The study by Yermilov et al. examining readmission to
hospital after PD for pancreatic cancer deals with both
concepts.2
Yermilov et al. provide a population-based analysis of
readmission to hospital within a year for patients with
pancreatic cancer undergoing PD in the state of California
over a 10-year period. The 59% one-year readmission rate
identified by these investigators informs us that this event,
inherently considered to be negative, will occur in most
patients. Accepting, as acknowledged by the authors, the
limitations of the use of administrative databases in the
examination of clinical issues, it seems that these
readmissions can be broadly categorized into two groups:
patients with perioperative morbidity as a consequence of
PD, and patients with progressive disease-related symp-
tomatology. In very few surgically treated malignancies are
we left with these two distinct clinical scenarios occurring
so commonly, and with relatively equal frequency, within a
year of operation. It may be useful to think of these two
issues separately in contemplating strategies to reduce such
readmissions.
POSTOPERATIVE MORBIDITY
Surgical technique in PD and its potential impact on
perioperative morbidity has been reasonably well studied
over the past 15 years.3 Randomized clinical trials have
been performed examining the roles of pyloric preservation
(no difference), extended lymphadenectomy (increased
morbidity), postoperative erythromycin (decreased mor-
bidity), and pancreatic anastomotic technique (no
difference) in PD. Several well-conducted cohort studies
have examined the impact on post-PD morbidity of pre-
operative biliary drainage (unclear effect, multicenter
randomized trial ongoing) and portal vein resection (no
increase). Important volume outcome relationships have
been identified with higher volume institutions and/or
surgeons demonstrating improved perioperative mortality
and lower length of stay (surrogate for perioperative mor-
bidity).4 Even more importantly, regionalization of PD has
been shown to be associated with improvements in post-
operative mortality5; this may also apply to postoperative
morbidity.
Given these and other important knowledge gains, how
can readmissions for PD-related morbidity be reduced?
Yermilov et al. suggest that better prevention strategies and
use of home health services may prevent some readmis-
sions, specifically those related to dehydration, deep-vein
thrombosis/pulmonary embolus, and gastritis/upper
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gastrointestinal bleeding. Although one could conceive that
specific strategies aimed at preventing such outcomes, or
treating patients as outpatients, may reduce readmissions,
there is little evidence to support this. A recent meta-
analysis demonstrated that strong data to suggest that
interventions may have a positive impact on readmissions
does not exist.6 The few successful existing interventions
tend to involve educational and resource components and
combine predischarge and postdischarge interventions. It is
possible that from a postoperative morbidity standpoint
after PD, the incremental gains yet to be made are small.
PROGRESSIVE PANCREATIC CANCER
SYMPTOMATOLOGY
Survivorship is a subject of increased emphasis in
patients undergoing cancer treatment; this is predominantly
based on the increasing number of patients surviving for
longer periods of time (e.g., breast cancer). Unfortunately,
overall survival in pancreatic cancer has not changed
appreciably over the past 30 years, and population-based
data of survival after PD for pancreatic cancer has demon-
strated minimal gains.7 Despite the aforementioned progress
in refining surgical technique, as well as major efforts to
define optimal adjuvant/neoadjuvant therapy approaches, it
is probably best to consider localized pancreatic cancer as
most commonly a systemic disease with less visible burden
of disease.8 Even in accepting this reality, however, both the
patient and the surgeon would consider readmission to
hospital within a year of PD for progression of disease a
failure. This failure, and its consequent impact on survi-
vorship, is predominantly an issue of patient selection.
Appropriate and optimal patient selection in pancreatic
cancer can be considered at several levels, including
screening and early detection, accurate and reproducible
preoperative radiographic assessment, surgical treatment,
use of adjuvant/neoadjuvant approaches, and surveillance.
As with postoperative morbidity, better long-term out-
comes are found in PD patients undergoing operation at
high volume institutions; this has been, at least in part,
attributed to selection factors. Critics of PD for pancreatic
cancer in the past have accused surgeons of selecting the
‘‘good actors’’ for resection, thus reporting ‘‘artificially
inflated’’ survival. We should embrace this approach at a
population level, seek the ‘‘good actors,’’ and provide
optimal treatment.9
Yermilov et al. have made an important contribution in
the surgical treatment of pancreatic cancer. They have
shown that readmission within a year of PD (1) is common;
(2) is underestimated by single-institution studies; and (3)
often occurs [3 months after PD and is attributable to
progressive disease. This work clearly illustrates the key
dichotomy of PD for pancreatic cancer—clinically impor-
tant perioperative morbidity and high death rate—and
reinforces the importance of patient selection. We can use
optimal patient selection to respond to the crusty senior
surgeon, but more importantly, pancreatic cancer patients
require it.
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